Dublin, Oct. 22, 2021 (GLOBE NEWSWIRE) -- The "Migraine Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global migraine drugs market exhibited strong growth during 2015-2020. Migraine is a neurological condition that causes unilateral or throbbing pain in the forehead, side of the head or around the eyes. The pain is often accompanied by autonomic symptoms, such as nausea, vomiting, photophobia and phonophobia. Migraine is generally diagnosed by examining the patient's medical history and symptoms, as well as by performing blood tests, and magnetic resonance imaging (MRI) and computerized tomography (CT) scans. At present, over the counter (OTC) medicines and prescribed injections are available to relieve the symptoms and reduce the frequency and severity of migraine attacks. These drugs are either taken regularly or during attacks or exacerbations of chronic pain.
A significant rise in the prevalence and diagnosis of migraine represents one of the key factors bolstering the market growth. Apart from this, the improvement in reimbursement policies for migraine medications, along with the escalating demand for precision medicines, is also contributing to the market growth. Furthermore, the growing demand for electrical nerve stimulating devices to treat migraine and the expected approval of new classes of drugs that are in late-stage pipeline and have higher clinical efficacy, such as the introduction of calcitonin gene-related peptide (CGRP) monoclonal antibodies, are also driving the market growth. Besides this, the testing of migraine drugs for the treatment of the coronavirus disease (COVID-19) is expected to create a positive influence on the market growth. For instance, Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, which was examining Zavegepant for the treatment of acute migraines, has commenced the clinical trial on the same drug to mitigate the neuro-immune consequences among COVID-19 patients. However, a decline in clinical visits and procedural treatment of migraines due to social distancing norms has impacted the market growth. Looking forward, the analyst expects the global migraine drugs market to grow at a CAGR of around 12% during 2021-2026.
Key Market Segmentation
The analyst provides an analysis of the key trends in each sub-segment of the global migraine drugs market, along with forecasts at the global, regional and country level from 2021-2026. The report has categorized the market based on region, treatment type, drug type, route of administration and distribution channel.
Breakup by Treatment Type
- Abortive Treatment
- Preventive Treatment
Breakup by Drug Type
- Triptans
- Ergot Alkaloids
- NSAIDs
- Acetylcholine Inhibitors/ Neurotoxins
- Ditans
- CGRP mAbs
- Others
Breakup by Route of Administration
- Oral
- Injectable
- Others
Breakup by Distribution Channel
- Hospital-Based Pharmacies
- Retail Pharmacies
- Others
Breakup by Region
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The report has also analysed the competitive landscape of the market with some of the key players being Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.
Key Questions Answered in This Report
- How has the global migraine drugs market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global migraine drugs market?
- What are the key regional markets?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global migraine drugs market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Migraine Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Treatment Type
6.1 Abortive Treatment
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Preventive Treatment
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Drug Type
7.1 Triptans
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Ergot Alkaloids
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 NSAIDs
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Acetylcholine Inhibitors/ Neurotoxins
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Ditans
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 CGRP mAbs
7.6.1 Market Trends
7.6.2 Market Forecast
7.7 Others
7.7.1 Market Trends
7.7.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Oral
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Injectable
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital-Based Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
11 SWOT Analysis
12 Value Chain Analysis
13 Porters Five Forces Analysis
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Abbott Laboratories
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Allergan PLC (Abbvie Inc.)
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 SWOT Analysis
15.3.3 Amgen Inc.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 SWOT Analysis
15.3.4 AstraZeneca PLC
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals)
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Eisai Co. Ltd.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Eli Lilly and Company
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Endo International PLC
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 GlaxoSmithKline PLC
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Johnson & Johnson
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Merck & Co.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Novartis AG
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
15.3.13 Pfizer Inc.
15.3.13.1 Company Overview
15.3.13.2 Product Portfolio
15.3.13.3 Financials
15.3.13.4 SWOT Analysis
15.3.14 Sanofi SA
15.3.14.1 Company Overview
15.3.14.2 Product Portfolio
15.3.14.3 Financials
15.3.14.4 SWOT Analysis
15.3.15 Teva Pharmaceutical Industries Limited
15.3.15.1 Company Overview
15.3.15.2 Product Portfolio
15.3.15.3 Financials
15.3.15.4 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/mo1kxw
